Physician profile
Sabreen Sarsour
NPI 1174252704
$961.14
in general payments reported to CMS, 2019-2025
13 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $109 · 2023: $333 · 2024: $247 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $852.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $321.10 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $142.64 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $101.88 | 2022-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $80.46 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $73.16 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $60.02 | 2024-2025 | Spravato, Invega Sustenna |
| Merck Sharp & Dohme LLC | $36.22 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Glaxosmithkline, LLC. | $34.70 | 2023-2025 | Arexvy, Shingrix, Bexsero |
| Lundbeck LLC | $33.96 | 2024-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $22.45 | 2022 | |
| Exact Sciences Corporation | $21.53 | 2024 | Cologuard Collection Kit |
| Pfizer INC. | $17.12 | 2025 | |
| Amphastar Pharmaceuticals, INC. | $15.90 | 2024 | Baqsimi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabreen Sarsour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.